Unicorn hunter Vivek Ramaswamy has cooked up a new deal with AstraZeneca. But what is it?
Something’s cooking at Vivek Ramaswamy’s Roivant Sciences. We just can’t say exactly what it is.
This morning Ramaswamy put out word that he’s bagged an experimental drug from AstraZeneca. He’s just not saying publicly what it is, where it’s positioned in the clinic or, for now, how it fits into the pipelines at the Roivant companies.
Here’s what we do know.
AstraZeneca has handed over global rights to an unspecified drug “outside of AstraZeneca’s main therapy areas” for an unspecified deal package. In a statement, Ramaswamy said this was the first such deal he’s done with AstraZeneca and he hopes for many more to follow.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
